Wednesday, September 30, 2015

UK launch for Perjeta in early Breast Cancer

Around 2,000 women in the UK with an aggressive form of breast cancer could now benefit from Roche’s Perjeta earlier in the treatment pathway after regulators expanded the drug’s license.
Perjeta is a first-in-class HER2 dimerisation inhibitor that works synergistically with Herceptin (trastuzumab) to block cancer cell survival and growth signals.The drug was initially licensed for previously-untreated advanced HER2-positive breast cancer, but can now also be used pre-surgery for locally advanced, inflammatory or early-stage disease at high risk of recurrence. “There is a need to bring effective medicines to patients with cancer earlier. Perjeta has already shown the longest survival benefit in patients with previously untreated advanced HER2-positive breast cancer, so it is very encouraging to see its authorisation in an earlier setting in order to further improve the long-term outcomes for patients with this aggressive disease,” noted Andrew Wardley, consultant in Medical Oncology at The Christie NHS Foundation Trust who was also involved in trials of the drug.




No comments:

Post a Comment